tbuckley/cabot-search huggingface dataset:
High Frequency of GATA2 Mutations in Cytogenetically Normal Acute Myeloid Leukemia with Biallelic CEBPA Mutations Identified by Exome Sequencing
Authors: Annika Dufour, Nikola Konstandin, Bianka Ksienzyk, Evelyn Zellmeier, Tobias Benthaus, Marjan Yaghmaie, Alexander Graf, Stefan Krebs, Andreas Hauser, Helmut Blum, Purvi Kakadia, Stephanie Schneider, Jan Braess, Bernhard Josef Woermann, Wolfgang E Berdel, Thomas Büchner, Wolfgang Hiddemann, Karsten Spiekermann, Stefan K Bohlander, Philipp A Greif
Journal: Blood (2011)
Health-Risk Behaviors among Long-Term Hematopoietic Cell Transplant (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.
Authors: Andrea Carter, Liton Francisco, K. Scott Baker, Stephen J. Forman, Marcia Grant, James G. Gurney, Leslie L. Robison, Daniel Weisdorf, Smita Bhatia
Journal: Blood (2005)
An Investigational Novel Orally Bioavailable Proteasome Inhibitor MLN9708/MLN2238 Triggers Cytotoxicity In Multiple Myeloma Cells Via p21- and Caspase-8-Dependent Signaling Pathway
Authors: Dharminder Chauhan, Ze Tian, Teru Hideshima, Nikhil C. Munshi, Paul G Richardson, Kenneth C. Anderson
Journal: Blood (2010)
Response Adapted Therapy: Using FDG-PET after Chemotherapy in Order To Restrict Indication for Radiotherapy in Children and Adolescents with Early Stages of Hodgkin’s Lymphoma (HL).
Authors: Christine G. Mauz-Koerholz, Regine Kluge, Ina Sorge, Barbara Merziger, Antje Krausse, Dirk Hasenclever, Friedrich H. Kamprad, H. Amthauer, Christiane Franzius, F. Gruenwald, Osama Sabri, Wolfgang Hirsch, Dieter Korholz
Journal: Blood (2005)
Renal transplantation in adults
Authors: Tom Nieto, Nicholas Inston, Paul Cockwell
Journal: BMJ (2016)

#### What you need to know

Renal transplantation improves quantity and quality of life compared with chronic dialysis.1 2 3 A UK general practice with 8000 patients will have around four patients with a functioning renal transplant, one patient on the transplant waiting list, and several under consideration for transplantation.4 Many medical problems in renal transplant recipients will be managed by non-specialist clinicians, and this article provides advice for the non-specialist on managing renal transplant patients.

Kidneys are transplanted following donation after brain stem death or after circulatory death and living donation. In the UK, the renal transplant surgical team is informed by NHS Blood and Transplant (NHSBT) when a deceased donor kidney becomes available for a patient on the renal transplant waiting list (fig 1⇓).



Fig 1  Classification of renal transplant operations in the UK



Allocation is based on a scoring system that includes immunological compatibility, recipient age, donor-recipient age parity, and time on waiting list.5 The median waiting time for a deceased donor transplant in the UK is two years and eight months, and this varies between centres.6 There are major international differences in donation and transplantation rates.7

Living donation is from a willing individual usually with a close emotional relationship with the recipient, although altruistic living donation is increasing.8 In a study of 36 UK patients who travelled overseas for commercial living donation transplantation, their clinical outcomes were significantly worse than those of 40 matched patients who received living donor transplants at their UK centre (composite graft and …
C/EBPβ Expression in ALK+ Anaplastic Large Cell Lymphomas (ALCL) Is Regulated by Stat3 Signaling Pathway.
Authors: Natasa Anastasov, Martina Rudelius, Margit Klier, Therese Dau, Daniela Angermeier, Stefania Pittaluga, Justus Duyster, Falko Fend, Mark Raffeld, Leticia Quintanilla-Martinez
Journal: Blood (2007)
Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia.
Authors: Laura Z. Rassenti, Donna S. Neuberg, Lang Huynh, William G. Wierda, John G. Gribben, Jennifer R. Brown, Ian W. Flinn, Kanti R. Rai, John C. Byrd, Neil E. Kay, Andrew W. Greaves, Thomas J. Kipps
Journal: Blood (2006)
Autophagy as a Target Pathway in Multiple Myeloma: A Forward Chemical Genetic Approach.
Authors: John P. Shen, Sanjay Divakaran, Letian Kuai, Xiang Wang, Shao-En Ong, Ravi Amaravadi, John Wood, Steven Carr, Stuart Schreiber, Stephen Haggarty, James Bradner
Journal: Blood (2007)
Chemokines and Cytokines Required for Migration of Mesechymal Stem Cells into Marrow or Injured Tissues.
Authors: Tatiana Tondreau, Meuleman Nathalie, Delforge Alain, Dejeneffe Marielle, Massy Martine, Mortier Christine, Bron Dominique, Lagneaux Laurence
Journal: Blood (2005)
Lyn Kinase Overexpression Is One of the Mechanisms of Resistance to Nilotinib In Chronic Myeloid Leukemia
Authors: Francois-Xavi er Mahon, Sandrine Hayette, Valerie Lagarde, Franck E Nicolini, Francis Belloc, Cedric Leroy, Serge Roche, Paul Manley, Coralie Belanger, Gabriel Etienne, Jean-Max Pasquet
Journal: Blood (2008)
Characterization of Ex Vivo Expanded Cord Blood Graft Treated with Chromatin Modifying Agents for Potential Clinical Use.
Authors: Kazumi Yoshinaga, Dolores Mahmud, Sudhakar Baluchamy, Ritesh Parajuli, Araki Hiroto, Valerie Lindgren, Damiano Rondelli, Nadim Mahmud
Journal: Blood (2007)
Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington’s Disease Models
Authors: Vahri Beaumont, Sheng Zhong, Hai Lin, WenJin Xu, Amyaouch Bradaia, Esther Steidl, Melanie Gleyzes, Kristian Wadel, Bruno Buisson, Fernando E. Padovan-Neto, Shreaya Chakroborty, Karen M. Ward, John F. Harms, Jose Beltran, Mei Kwan, Afshin Ghavami, Jenny Häggkvist, Miklós Tóth, Christer Halldin, Andrea Varrone, Christoph Schaab, J. Nikolaj Dybowski, Sarah Elschenbroich, Kimmo Lehtimäki, Taneli Heikkinen, Larry Park, James Rosinski, Ladislav Mrzljak, Daniel Lavery, Anthony R. West, Christopher J. Schmidt, Margaret M. Zaleska, Ignacio Munoz-Sanjuan
Journal: Neuron (2016)
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
Authors: John R Teerlink, G Michael Felker, John J V McMurray, Scott D Solomon, Kirkwood F Adams, John G F Cleland, Justin A Ezekowitz, Assen Goudev, Peter Macdonald, Marco Metra, Veselin Mitrovic, Piotr Ponikowski, Pranas Serpytis, Jindrich Spinar, János Tomcsányi, Hans J Vandekerckhove, Adriaan A Voors, Maria Laura Monsalvo, James Johnston, Fady I Malik, Narimon Honarpour
Journal: The Lancet (2016)
HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era,
Authors: Silvia Montoto, Kate Shaw, Jessica Okosun, Shreyans Gandhi, Paul Fields, Andrew Wilson, Milensu Shanyinde, Kate Cwynarski, Robert E. Marcus, Johannes de Vos, Anna Marie Young, Melinda Tenant-Flowers, Chloe Orkin, Margaret Johnson, Daniella Chilton, John G. Gribben, Mark Bower
Journal: Blood (2011)
Disease-Free Survival in Adult Patients with Acute Leukemia and Advanced CML Supports Use of Double-Unit Cord Blood Grafts As an Immediate Alternative to 8/8 HLA-Matched Unrelated Donors (URD)
Authors: Doris M. Ponce, Patrick Hilden, Sean M. Devlin, Molly Maloy, Marissa N Lubin, H.R. Castro-Malaspina, Jenna D Goldberg, Ann A. Jakubowski, Richard Meagher, Esperanza B Papadopoulos, Miguel-Angel Perales, Craig S. Sauter, Marcel R.M. van den Brink, James W. Young, Nancy A. Kernan, Richard J O'Reilly, Andromachi Scaradavou, Sergio Giralt, Juliet N. Barker
Journal: Blood (2014)
Primary Prophylaxis Using Peg-Filgrastim Is Useful Preventing Severe Infections and Neutropenia in Patients Diagnosed with Non Hodgkin Lymphoma (NHL). Report of Latin America International Multicenter Study
Authors: Luis Villela, Alberto Villalobos, Gustavo Reyes-Brena, Jorge Duque, Juan Carlos Solís-Poblano, Eduardo Reynoso, Roberto Ovilla, Alejandro Camacho, Norberto Vazquez, Oscar Garces, Enrique Pedrasa, Salvador Silva
Journal: Blood (2008)
Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.
Authors: Gerlinde Wernig, Michael G. Kharas, Rachel Okabe, Sandra A. Moore, Dena S. Leeman, Dana E. Cullen, Maricel Gozo, Elizabeth P. McDowell, Ross L. Levine, John Doukas, Chi Ching Mak, Glenn Noronha, Michael Martin, Yon D. Ko, Benjamin H. Lee, Richard Soll, Ayalew Tefferi, John D. Hood, D. Gary Gilliland
Journal: Blood (2007)
Dynamic Defense System Against HMGB1, a Proinflammatory and Lethal Mediator in Severe Infections and Malignancies.
Authors: Takashi Ito, Kazuhiro Abeyama, Ko-ichi Kawahara, Kamal K. Biswas, Tomonori Uchimura, Shingo Yamada, Teruto Hashiguchi, Ikuro Maruyama
Journal: Blood (2004)
The Guanine Exchange Factor RalGDS Is Involved in Regulated Exocytosis of Weibel-Palade Bodies from Endothelial Cells.
Authors: Jan Voorberg, Mariska G. Rondaij, Karina A. Gijzen, Ruben Bierings, Erica Sellink, Mar Fernandez-Borja, Jan A. van Mourik
Journal: Blood (2005)
Clinicopathologic Significance of CD11c, CD16 and FOXP3 Expression in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Receiving Rituximab, Cyclophosphamide, Anthracycline, Vincristine, and Prednisolone (R-CHOP) Combination Chemotherapy
Authors: Sung Yong Oh, Jin Sook Jung, Sung Hyun Kim
Journal: Blood (2012)
Mesenchymal Stem Cells (MSC) Promote Aggressive Behavior of Human Breast Cancer Cells (MCF-7) in Vitro- the Role Cytokines (TNF-alpha) and Chemokines
Authors: Jan Cerny, Yingwang Liu, Nathan Moore, Glennice Bowen, Anna M Cerny, Evelyn Kurt-Jones, Susan Erdman, JeanMarie Houghton
Journal: Blood (2008)
A Homozygous Telomerase Reverse Transcriptase T Motif Variant Resulting in Markedly Reduced Telomerase Repeat Addition Processivity in Siblings with Hoyeraal Hreidarsson Syndrome
Authors: M. Monica Gramatges, Xiaodong Qi, Ghadir S. Sasa, Julian J-L Chen, Alison A. Bertuch
Journal: Blood (2012)
Molecular Characterization of AML1 (RUNX1) Amplification: A Poor Risk Chromosomal Marker in Acute Lymphoblastic Leukaemia (ALL).
Authors: Jon C. Strefford, Frederic van Delft, Manoj Raghavan, Hazel M. Robinson, Anthony V. Moorman, Bryan D. Young, Vaskar Saha, Christine J. Harrison
Journal: Blood (2004)
Protein Z Levels Could Help To Predict Obstetrical Complications and Arterial Thrombosis in Patients with Antiphospholipid Antibodies.
Authors: Annick Ankri, Isabelle Martin-Toutain, Kiarach Goldar, Marie-Claude Diemert, Danielle Vauthier-Brouze, Jean-Charles Piette
Journal: Blood (2006)
Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin’s Disease (NLPHD).
Authors: Sandra J. Horning, Nancy L. Bartlett, Sheila Breslin, Ranjana H. Advani, Richard T. Hoppe, Bradley C. Ekstrand, Jennifer B. Lucas
Journal: Blood (2007)
Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
Authors: Natalia Arenas-Ramirez, Chao Zou, Simone Popp, Daniel Zingg, Barbara Brannetti, Emmanuelle Wirth, Thomas Calzascia, Jiri Kovarik, Lukas Sommer, Gerhard Zenke, Janine Woytschak, Catherine H. Regnier, Andreas Katopodis, Onur Boyman
Journal: Science Translational Medicine (2016)

An antibody to human IL-2 phenocopies CD25 and improves IL-2–based cancer immunotherapy.
Novel formulations of therapeutic antibodies with hyaluronic acid (HA) in the treatment of colorectal cancer: a pre-clinical evaluation
Authors: Gary R. Brownlee, Jeanette L. Falzon, Minh Pho, Natalie K. Thomas, Christopher J. Vearing, Debbie L. Rigby, Tracey J. Brown
Journal: Cancer Research (2006)

682  INTRODUCTION: Knowledge of the molecular basis for cancer has been used to develop a new generation of therapies designed to target specific molecular processes that are essential for tumor growth and survival. Two such therapies employ the monoclonal antibodies, bevacizumab (Avastin®) and cetuximab (Erbitux®,ERB), which are routinely used for the treatment of metastatic colorectal cancer. A novel generation of anticancer formulations based on the naturally occurring polysaccharide HA, is currently under development which exploit the unique physiochemical and biological properties of HA, enabling it to direct entrained anticancer agent(s) to over-expressed CD44 receptors. To date HA formulations have been used with standard cytotoxic drugs. The objective of this study was to evaluate if HA could provide the basis for improved formulations of Erbitux® (ERB) monotherapies and ERB/chemotherapy combinations. The assessment of the formulation HyERB™ comprising HA and Erbitux® and the combination therapy of HyERB™ with HyCAMP™ (comprising HA and Camptosar®) in colon cancer xenografts is described. METHODOLOGY: LIM1215 colon cancer xenografts were subcutaneously injected into the mammary fat pad of athymic nude Balb/c mice. Treatment groups (n=8) commenced when tumors reached 50-100mm3. The four treatment groups were: 1) HyERB™(150/0.5), 2) ERB(0.5), 3) HA (150), and 4) saline [all dosage amounts shown in brackets are in mg/kg]. Therapies were delivered IV on day 1 and 4 for a total of 5-weeks. Combination therapies included: 1) HyERB™(150/0.5)/HyCAMP™(26.6/50) and 2) ERB(0.5)/CAMP(50). The dosing regimen for HyCAMP™ or CAMP was day 1 of a 7-day cycle for a total of 5-weeks. Mice were observed for 120 days for tumor regrowth. RESULTS: Mice receiving HyERB™ monotherapy displayed a significant reduction in tumor size, which by day 29 was circa -29% of the original measurement compared to mice receiving ERB therapy, where all tumors were ±1% of the original measurement. During the tumor rebound period, tumor progression was more evident in the ERB group where 86% of tumors were assessed as ‘stable disease’ while 50% of HyERB™-treated tumors demonstrated partial response or stable disease. In combination therapies, the tumor size for HyERB™/HyCAMP™ at days 8, 11 and 15 was significantly smaller than in animals treated with ERB/CAMP. No treatment toxicities were observed.CONCLUSIONS: The formulation of HA with cetuximab (HyERB™) produced a significant anti-tumor response, whereas the antibody alone produced a cytostatic response in the LIM1215 (CD44 positive, EGFR positive) colon xenograft model. This increased efficacy was also achieved when using HA formulations in combination ERB/chemotherapy treatment regimens.
Phase I and Pharmacokinetic (PK) Study of Everolimus (RAD001) in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL).
Authors: Michinori Ogura, Toshiki Uchida, Dai Maruyama, Naokuni Uike, IIseung Choi, Kenichi Ishizawa, Kuniaki Itoh, Kiyoshi Ando, Masafumi Taniwaki, Naomi Shimada, Ken Kobayashi, Kensei Tobinai
Journal: Blood (2009)
A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study
Authors: Simona Sammassimo, Alberto Agazzi, Simona Bassi, Liliana Calabrese, Paola Bertazzoni, Anna Vanazzi, Angelo Gardellini, Federica Gigli, Giovanna Andreola, Giovanni Martinelli
Journal: Blood (2010)
The Dual PI3K and mTOR Kinase Inhibitor NVP-BEZ235 Induces Cell Cycle Arrest in Acute Lymphoblastic Leukemia Cells and Potentiates the Cytotoxicity of Dexamethasone, Cytarabine and Doxorubicin.
Authors: Catrin Schult, Meike Dahlhaus, Anett Sekora, Sandra Lange, Mathias Freund, Christian Junghanss
Journal: Blood (2009)
Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM).
Authors: Marcello Rotta, Barry Storer, Firoozeh Sahebi, Judith A. Shizuru, Bruno Benedetto, Thoralf Lange, Peter A. McSweeney, Michael A. Pulsipher, Parameswaran Hari, Richard T. Maziarz, Edward D. Agura, Thomas Chauncey, Frederick R. Appelbaum, Mohamed L. Sorror, William Bensinger, Brenda M. Sandmaier, Rainer F. Storb, David G. Maloney
Journal: Blood (2007)
A Pathophysiological Role for ADAMTS13 in Thrombotic Thrombocytopenic Purpura (TTP) without Severe ADAMTS13 Deficiency.
Authors: Johanna A. Kremer Hovinga, James N. George, Sara K. Vesely, Deirdre R. Terrell, Ulrich Budde, Irmela Sulzer, Bernhard Lammle
Journal: Blood (2006)
Response Assessment after an Inductive CHOP or CHOP-Like Regimen with or without Rituximab in 103 Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Integrating 18Fluorodeoxyglucose Positron Emission Tomography (PET) to the International Workshop Criteria (IWC).
Authors: Jehan Dupuis, Emmanuel Itti, Alain Rahmouni, Jean-Didier Rain, Christian Gisselbrecht, Karim Belhadj, Taoufik El Gnaoui, Isabelle Gaillard, Chieh Lin, Nicolas Mounier, Philippe Gaulard, Michel Meignan, Felix Reyes, Corinne Haioun
Journal: Blood (2006)
Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.
Authors: James E. Hoffman, Hani Hassoun, Heather Landau, Elizabeth Hoover, Adam Cohen, Stephen Nimer, Raymond Comenzo
Journal: Blood (2008)
Age Does Not Influence Long-Term Quality of Life (QOL) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for AML/MDS.
Authors: Munir Shahjahan, Jorge Alamo, Sergio Giralt, Michelle Detry, Mark Munsell, Elihu Estey, Richard Champlin, Marcos de Lima
Journal: Blood (2004)
Comprehensive Analysis of Homeobox Genes in Hodgkin Lymphoma Cell Lines Identified Dysregulated Expression of HOXB9 Mediated by Constitutive Active ERK5 Signalling Pathway and BMI1.
Authors: Stefan Nagel, Cristof Burek, Letizia Venturini, Michaela Scherr, Hilmar Quentmeier, Corinna Meier, Andreas Rosenwald, Hans G. Drexler, Roderick A.F. MacLeod
Journal: Blood (2006)
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL)
Authors: Marta Coscia, Micol Rigoni, Chiara Riganti, Candida Vitale, Ivana Campia, Valentina Griggio, Myriam Foglietta, Barbara Castella, Patrizia Sciancalepore, Maria Elisa Canepari, Marta Robino, Daniela Drandi, Marco Ladetto, Amalia Bosia, Mario Boccadoro, Massimo Massaia
Journal: Blood (2012)
Association between the CDHR3 rs6967330 risk allele and chronic rhinosinusitis
Authors: Eugene H. Chang, Amanda L. Willis, Hilary C. McCrary, George T. Noutsios, Christopher H. Le, Alexander G. Chiu, Corrine J. Mansfield, Danielle R. Reed, Steven G. Brooks, Nithin D. Adappa, James N. Palmer, Noam G. Cohen, Debra A. Stern, Stefano Guerra, Fernando D. Martinez
Journal: Journal of Allergy and Clinical Immunology (2016)
Imatinib 400 mg in Early Chronic Phase CML: Results of a Multicentric, Prospective Non Academical Observational Study (by the GIMEMA CML Working Party).
Authors: Gianantonio Rosti, Fausto Castagnetti, Ilaria Iacobucci, Marilina Amabile, Francesca Palandri, Panagiota Giannoulia, Giuliana Alimena, Nicoletta Testoni, Simona Luatti, Bruno Martino, Giorgina Specchia, Serena Rupoli, Adele Capucci, F. Cavazzini, Franca Radaelli, Ester Orlandi, Giovanna Rege Cambrin, Emilio Usala, Nicoletta Testoni, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, Michele Baccarani
Journal: Blood (2006)
ACTR-29. FINAL RESULTS FROM THE AXIG TRIAL: A RANDOMIZED PHASE II CLINICAL TRIAL INVESTIGATING AXITINIB ALONE OR IN COMBINATION WITH CCNU IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Authors: Johnny Duerinck, Stephanie Du Four, Frank Bouttens, Vincent Verschaeve, Cristo Chaskis, Chantal Andre, Frank Van Fraeyenhove, Nicky D’haene, Isabelle Salmon, Bart Neyns
Journal: Neuro-Oncology (2016)

Axitinib is a small molecule TKI with high affinity and specificity for the VEGFRs and has demonstrated anti-tumor activity in patients with recurrent glioblastoma (rGB). The AXIG trial (NCT01562197) is a randomized clinical trial investigating at first the activity of axitinib monotherapy (AXI-arm) versus physicians best alternative choice of therapy (Duerinck et al. JNO Mar2016) and, following amendment, axitinib monotherapy versus axitinib plus lomustine (Duerinck et al. ASCO AM2016) in patients with rGB. A pooled analysis including all patients exposed to axitinib was performed. Between August 2011 and July 2015, 78 pts were enrolled in the trial and initiated axitinib monotherapy (N:50; AXI) or axitinib plus lomustine (N:28; AXILOM). Median age was 55y [range 18–80], 50M/28F. Baseline characteristics were well balanced between study arms. Thirteen pts in the AXI-arm crossed-over at the time of progression(AXIseqLOM). Treatment was generally well tolerated. AXILOM pts were at higher risk for grade 3/4 neutropenia (0% vs. 21%) and thrombocytopenia (4% vs 29%). BORR in the AXI arm was 26% (2CR/11PR) vs. 43% in the AXILOM-arm (1CR/11PR). BORR after adding CCNU to axitinib at progression on axitinib (AXIseqLOM) was 1 PR and 8SD. 6mPFS and OS rates were respectively 26% (95% CI 14–38) vs 17% (95% CI 2–32), and 54% (95% CI40-68) vs. 53% (95% CI34-73) for pts treated in the AXI vs. AXILOM-arms. When the time-to-second progression was taken into account for the 9 AXIseqLOM patients who experienced PR or SD following the addition of lomustine at first PD on axitinib, 6-mths PFS was 39% (95% CI21-57). No significant correlation was found between clinical outcome measures and the MGMT promoter methylation status or IDH1/2 mutation status. Axitinib has single-agent activity in patients with rGB; upfront combination of axitinib and LOM did not significantly increase progression-free or overall survival in patients with recurrent glioblastoma.
The Second Signal in Antigen-Presenting Cells: Complementary JAK-1 Directs Pro- and Anti-Inflammatory Cytokine Production Induced by CD40L.
Authors: Michael Conzelmann, Andreas Wagner, Anke Hildebrandt, Elena Rodionova, Michael Hess, Annika Zota, Thomas Giese, Christine Falk, Stephen Breit, Markus Hecker, Anthony D. Ho, Peter Dreger, Thomas Luft
Journal: Blood (2009)
MRI Assessment of Pituitary Iron and Volume in Thalassemia, and Relation to Hypothalamic-Pituitary-Gonadal Axis Function (HPG): A Feasibility Study.
Authors: Zhiyue J. Wang, Roland Fischer, Ellen Butensky, Lynne Neumayr, Sylvia Titi Singer, Phillip Lee, Zili Chu, Jill V. Hunter, John Firebaugh, Elliott Vichinsky, Paul Harmatz
Journal: Blood (2006)
PVN1: A Phase 2 Study of Pegylated Interferon-α2a in Polycythemia Vera (PV) by the “PV-Nord” Group. Preliminary Report of Efficacy and Safety.
Authors: Jean-Jacques Kiladjian, Bruno Cassinat, Pascal Turlure, Sylvia Bellucci, Nathalie Cambier, Murielle Roussel, Marie-José Grange, Jean-Didier Rain, Christine Chomienne, Pierre Fenaux
Journal: Blood (2005)
LP49 : Sofosbuvir containing regimes to patients with HCV genotype 3 infection. A scandinavian real-life experience
Authors: O. Dalgard, N. Weis, G. Noraberg, K. Isaksen, A. Oevrehus, M. Skalshøj Skjær, O. Weiland
Journal: Journal of Hepatology (2015)
Definition of RAEB-I and RAEB-Ii According to the Who Classification of Myelodysplastic Syndromes (MDS): Problems Emerging from a Large Multicenter Registry.
Authors: Alessandro Levis, L. Godio, M. Girotto, M. Bonferroni, T. Callegari, G. Cametti, G. Ciravegna, A. Darbesio, D. Ferrero, F. Ficara, R. Freilone, S. Gatto, F. Marmont, F. Salvi, P. Scaravaglio, A. Stacchini, S. Tardia, A. Tonso, M. Boccadoro, A. Gallamini, E. Gallo, C. Marinone, G. Saglio
Journal: Blood (2004)
Clinical Outcome in Patients with AML Exhibiting Poor Mobilization of Progenitor Cells.
Authors: Wanda Knopinska-Posluszny, Michal Taszner, Jan M. Zaucha, Lucja Kachel, Anna Czyz, Lidia Gil, Jerzy Holowiecki, M. Komarnicki, Andrzej Hellmann
Journal: Blood (2006)
Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011
Authors: Aref Al-Kali, Raoul Tibes, James M. Foran, Mrinal M Patnaik, Naseema Gangat, Adam C Bartley, Michelle Elliott, Mark R Litzow, Ronald S. Go
Journal: Blood (2015)
Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study
Authors: Keith Sigel, Juan Wisnivesky, Kristina Crothers, Kirsha Gordon, Sheldon T Brown, David Rimland, Maria C Rodriguez-Barradas, Cynthia Gibert, Matthew Bidwell Goetz, Roger Bedimo, Lesley S Park, Robert Dubrow
Journal: The Lancet HIV (2016)
A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI-28090) in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL).
Authors: Ann Mohrbacher, Shamel Sanani, David Irwin, Byron M. Espina, Catherine Madrid, Luigi Lenaz, Rosamerlinda Rosales
Journal: Blood (2004)